Share this Page:
A study investigating the prognostic and predictive value of a type of white blood cell called tumour-infiltrating B lymphocytes for tyrosine kinase inhibitor (TKI) therapy in people with metastatic renal cell carcinoma (mRCC) has been published in the journal OncoImmunology recently.
These results from the study showed that people with mRCC who were positive for tumour-infiltrating B lymphocytes had a better therapeutic response to sunitinib, longer overall survival and longer progression-free survival.
The researchers suggest that combining the tumour-infiltrating B lymphocyte status with the International Metastatic RCC Database Consortium (IMDC) risk score provides a better prediction for overall survival in mRCC patients treated with TKIs than the IMDC risk score alone. The presence of tumour-infiltrating B lymphocytes was also a predictive biomarker for response to TKIs.
